Study of the Effect of Eicosanoids on Contractile Activity of Pregnant Human Myometrium in Pathological Situation (EAU2)

This study is currently recruiting participants.
Verified January 2013 by Universitaire de Sherbrooke
Sponsor:
Collaborator:
Fonds de la Recherche en Santé du Québec
Information provided by (Responsible Party):
Jean-Charles Pasquier, MD, PhD, Universitaire de Sherbrooke
ClinicalTrials.gov Identifier:
NCT00939744
First received: July 14, 2009
Last updated: January 15, 2013
Last verified: January 2013

July 14, 2009
January 15, 2013
May 2009
February 2014   (final data collection date for primary outcome measure)
effect of eicosanoids on contractile activity of myometrium of pregnant women with pathological situations [ Time Frame: during c-section ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00939744 on ClinicalTrials.gov Archive Site
  • effect of enzymatic inhibitors on contractile activity of myometrium from pregnant women with pathological situations [ Time Frame: during c-section ] [ Designated as safety issue: No ]
  • detection of enzymes from the different pathways [ Time Frame: after c-section ] [ Designated as safety issue: No ]
  • quantification of eicosanoids in different tissues [ Time Frame: after c-section ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Study of the Effect of Eicosanoids on Contractile Activity of Pregnant Human Myometrium in Pathological Situation
Study of the Effect of Eicosanoids on Contractile Activity of Pregnant Human Myometrium in Pathological Situation.

Recent studies show that EET and 20-HETE have important biological effects, particularly in the vascular system. The investigators studied the effect of eicosanoids on the gravid rat uterus. The results suggest that 20-HETE had an tocolytics effect on gravid uterus. In the previous study, we demonstrated that the enzymes of the pathway of EET were present in human uterine tissues. Moreover, the addition of an inhibitor of degradation of EET had an tocolytic effect on the human myometrium, as the exogenous addition of 8.9, 14,15-EET and 20-HETE.

Objectives:

Primary objective: To compare the balance of different metabolic pathways of arachidonic acid (AA) of the pregnant human myometrium in pathological situations (preterm labor, uterine atony, prolonged pregnancy).

Specific objectives: i) To study the effect of derived from the AA on in vitro contractile activity of normal and pathological uterine tissues, and ii) detect and quantify the different sub-products of metabolism of AA in the uterine tissues (myometrium, fetal membranes and placenta).

The management of uterine contraction is in the heart of modern obstetrics year, yet the progress made in other specialties, based on the study of smooth muscle have not yet been transposed in obstetrics. A better understanding of systems for regulating the contraction is important in terms of 1) new physiological knowledge, but it could also be the source of 2) modification of strategies to take care of premature delivery (new Tocolytic), or 3) improving the efficiency of uterine muscle during delivery or 4) for treatment of patients with prolonged pregnancy.

It is a clinical study with a slope fundamental aims to examine the metabolic pathways of AA of human myometrium and their functional roles according to their clinical profile divided into three contractile pathological situations - threat of premature delivery, dynamic dystocia, prolonged pregnancy - and two groups of patients at term: a group before work and group work.

The sampling method. After birth, a biopsy will be perform from the lower segment of the uterus. After caesarean sections of membrane and placenta are collected.

The substances studied during isometric tension tests are part of the three degradation pathways of the AA.

  1. new eicosanoids in cumulative dose (8,9-EET, 11,12-EET, 14,15-EET, 20-HETE), and in combination
  2. enzyme inhibitors of the eicosanoids pathway (AUDA, MS-PPOH, DDMS), and the COX and LOX pathways (indomethacin), alone or in combination.
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

uterus biopsy

Non-Probability Sample

women who will have a c-section at the CHUS

  • Obstetric Labor Complications
  • Prolonged Pregnancy
Not Provided
EAU2
Women who will have a c-section at the CHUS
Corriveau S, Pasquier JC, Blouin S, Bellabarba D, Rousseau É. Chronic levothyroxine and acute T3 treatments enhance the amplitude and time course of uterine contractions in human. Am J Physiol Endocrinol Metab. 2013 Mar 1;304(5):E478-85. doi: 10.1152/ajpendo.00346.2012. Epub 2012 Dec 18.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
130
March 2014
February 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • all women who will have a c-section

Exclusion Criteria:

  • induction of labor,
  • child with malformation,
  • birth weight less than 2500 grams or greater than 4500g
Female
18 Years to 40 Years
No
Contact: Stéphanie Corriveau, BSc 819 346-1110 ext 13875 stephanie.corriveau@usherbrooke.ca
Contact: Simon Blouin, PhD 819 346-1110 ext 13877 syblouin.chus@ssss.gouv.qc.ca
Canada
 
NCT00939744
09-040
No
Jean-Charles Pasquier, MD, PhD, Universitaire de Sherbrooke
Universitaire de Sherbrooke
Fonds de la Recherche en Santé du Québec
Principal Investigator: Jean-Charles Pasquier, MD, PhD Centre hospitalier de l'Université de Sherbrooke
Principal Investigator: Rousseau Éric, PhD Universitaire de Sherbrooke
Universitaire de Sherbrooke
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP